// App-Quantinova.ai

TPS2668 : Association of combined phase I/II study of a novel bicyclic peptide and MMAE conjugate BT8009 in patients with advanced malignancies with Nectin-4 expression.

Researchers

Presenter

  • Meredith McKean

Principal Investigators

  • Gerald Steven Falchook

  • Johanna C. Bendell

  • Babar Bashir

  • Neil Palmisiano

  • Roshawn Watson

  • Mary-Anne McKenna

  • Carly Campbell

  • Dominic Paul Smethurst

  • Phil Jeffrey

  • Julius Kirui

  • Hendrik-Tobias Arkenau

  • Elisa Fontana

Medical Centers

  • Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN, Sarah Cannon Research Institute at HealthONE, Denver, CO, Sarah Cannon Research Institute/Tennessee Oncology PLLC, Nashville, TN, Sidney Kimmel Cancer Center, Thomas Jefferson University Hospital, Philadelphia, PA, Bicycle Therapeutics, Lexington, MA

  • Bicycle Therapeutics Ltd, Cambridge, United Kingdom

  • Sarah Cannon Development Innovations, Nashville, TN, Sarah Cannon Research Institute, United Kingdom

  • NCRI, London, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Cardiovascular (CVS)

Disease

  • Solid malignancies

  • Brain metastasis

  • Hypertension

Biomarkers

  • Nectin Cell Adhesion Molecule 4

  • Cytochrome P450 Family 3 Subfamily A Member 4

Drug/Treatment

  • Enfortumab vedotin

  • Nivolumab

  • monomethyl auristatin E

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I/II

Study Id's

  • NCT04561362

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved